tirzepatide cardiovascular outcomes trial results july 2025 In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣ ⁣ Read the full SURPASS-CVOT and Research Summary TP-Active Subscription:3 months Consumer Option - MHBP

tirzepatide cardiovascular outcomes trial results july 2025 In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣ ⁣ Read the full SURPASS-CVOT and Research Summary TP-Active Subscription:3 months Consumer Option - MHBP

Consumer Option - MHBP Federal Health Plans

Regular monitoring also catches any rare thyroid-related side effects early, though tirzepatide itself does not trigger hypothyroidism or thyroid inflammation

TP-Active

Subscription:3 months

Medically supervised weight loss with GLP-1 options, personalized prescriptions, and expert 1:1 counseling